正文
Dose optimization of PF-07248144, a first-in-class KAT6 inhibitor, in patients (pts) with ER+/HER2− metastatic breast cancer (mBC): Results from phase 1 study to support the recommended phase 3 dose (RP3D).
讲者: Patricia LoRusso, PhD, FASCO, DO | Yale School of Medicine
摘要号：1021
KM-10A/KCSG BR18-13：曲妥珠单抗联合gedatolisib用于2种及以上HER2导向化疗后进展的HER2阳性转移性乳腺癌
Phase II study of trastuzumab-pkrb plus gedatolisib in patients with HER2-positive metastatic breast cancer who progressed after 2 or more HER2-directed chemotherapies (KM-10A/KCSG BR18-13).
讲者: KyongHwa Park, MD, PhD | Division of Oncology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine
Rapid Oral Abstract Session
乳腺癌-局部/区域/辅助
Breast Cancer—Local/Regional/Adjuvant
专场时间：
2025年6月1日 08:00-09:30
专场主席：
Eileen Connolly, MD, PhD Columbia University Irving Medical Center；Matteo Lambertini, MD U.O. Clinical Oncology, IRCCS Ospedale Policlinico San Martino, University of Genova
专场地点：
Hall B1 | Live Stream
摘要号：LBA509
NRG-BR003 III期试验：多柔比星+环磷酰胺序贯周疗紫杉醇±卡铂治疗淋巴结阳性/高危淋巴结阴性三阴性乳腺癌的随机研究
NRG-BR003: A randomized phase III trial comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative TNBC.
讲者:Vicente Valero, MD | The University of Texas MD Anderson Cancer Center
摘要号：510
评估早期TNBC同源重组缺陷（HRD）患者新辅助奥拉帕利/卡铂对比多西他赛/表柔比星/环磷酰胺（TAC）疗效和安全性的前瞻性随机 2 期试验：ABCSG 45 试验的初步结果
Prospective randomized phase II trial to assess the efficacy and safety of neo-adjuvant olaparib/carboplatin (OC) in comparison to docetaxel/epirubicin/cyclophosphamide (TAC) in patients with early triple-negative breast cancer (TNBC) with homologous recombination deficiency (HRD): Primary results from the ABCSG 45 trial.
讲者: Christian F. Singer, MD, MPH | Department of Obstetrics and Gynecology and Center for Breast Health, Comprehensive Cancer Center, Medical University of Vienna and Austrian Breast and Colorectal Cancer Study Group
摘要号：511
早期TNBC患者以疗效为导向的新辅助戈沙妥珠单抗和帕博利珠单抗（SG/P）治疗的 2 期研究：NeoSTAR 试验结果
A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial.
讲者: Rachel Occhiogrosso Abelman, MD | Massachusetts General Hospital Cancer Center, Harvard Medical School
摘要号：512
Promise 研究：绝经后导管原位癌女性术前 CE/BZA 对比安慰剂的随机临床试验
The Promise study: A presurgical randomized clinical trial of CE/BZA vs placebo in postmenopausal women with ductal carcinoma in situ
讲者: Swati Kulkarni, MD | Northwestern University Feinberg School of Medicine
摘要号：513
WinPro试验：一项针对绝经后早期HR+乳腺癌患者内分泌治疗±孕酮的机会窗研究
The WinPro trial: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer.
讲者: Lucy Haggstrom, MD | St Vincent's Hospital Sydney and University of New South Wales
摘要号：514
法国多中心、随机 SHARE 试验比较绝经后早期低危乳腺癌女性全乳照射与加速部分乳腺照射的早期结果：毒性和美容结局分析
Early results of the French multicenter, randomized SHARE trial comparing whole breast irradiation versus accelerated partial breast irradiation in postmenopausal women with early-stage low risk breast cancer: Analysis of toxicity and cosmetic outcomes.
讲者:Yazid Belkacemi | AP-HP, Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, University of Paris Est Creteil (UPEC)
摘要号：515
达尔西利联合内分泌治疗用于HR+/HER2-早期乳腺癌辅助治疗：随机、III期DAWNA-A试验
Dalpiciclib (Dalp) plus endocrine therapy (ET) as adjuvant treatment for HR+/HER2– early breast cancer (BC): The randomized, phase 3, DAWNA-A trial.
讲者: 邵志敏 | 复旦大学附属肿瘤医院
摘要号：516
NATALEE 研究中瑞波西利+非甾体芳香化酶抑制剂（NSAI）的疗效和安全性：按绝经状态和年龄分析
Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in NATALEE: Analysis across menopausal status and age.
